Health awareness

Measles: signs and symptoms

Learn more about what the measles virus is and how measles spreads

March 13, 2025

Share this article

.st0{fill:#00857C;}

little girl with measles
mom holding child with measles

What is measles?

Measles is a highly contagious viral disease that can affect people of all ages but is most common in children. The virus lives in the mucus of the nose and throat of an infected person.

Measles spreads through the air when an infected person coughs or sneezes. Symptoms appear 7 to 14 days after contact with the virus.

Common measles symptoms include:

High fever

(may spike to more than 104°F)

Cough

Runny nose

Red, watery eyes

(7-14 days after contact with the virus)

Spots in mouth

(2-3 days after symptoms begin)

Rash

(3-5 days after symptoms begin)

How measles spreads

icon
Is measles airborne?

The measles virus can live for up to two hours in an airspace after an infected person leaves an area.

icon
How contagious is measles?

If one person has measles, up to 90% of unvaccinated people close to that person will also become infected.

icon
How long is measles contagious for?

Infected people can spread measles to others four days before through four days after the rash appears.

icon
How long is the measles incubation period?

After being exposed to the measles virus, it can incubate for up to 21 days. An incubation period is how long it takes for you to develop symptoms after exposure to an infectious disease.

icon
Does measles cause complications?

Measles can cause health complications. Common complications include ear infections and diarrhea. Serious complications include pneumonia and encephalitis (an inflammation of the brain). Measles may impact the daily lives of patients and their caretakers (e.g., can result in lost work time or missed school days).

Measles can be serious and lead to complications 

  • About 1 in 5 unvaccinated people in the U.S. who get measles are hospitalized.
  • As many as 1 out of every 20 children with measles get pneumonia, the most common cause of death from measles in young children.
  • Approximately 1 to 3 of every 1,000 children who become infected with measles will die from respiratory and neurologic complications.

Understanding measles outbreaks

Before the vaccine became available in 1963, an estimated 3 to 4 million Americans contracted measles each year; an estimated 48,000 people in the U.S. were hospitalized and there were approximately 400 to 500 deaths annually.

icon

Endemic (regularly occurring within an area or community) measles was declared eliminated in the U.S. in 2000.

icon

2019 saw the greatest number of measles cases reported in the U.S. since 1992.

icon

2024 has seen continuous measles outbreaks with 13 measles outbreaks as of July reported across the U.S.

When you’re contagious with measles, up to 90% of the people around you who are not vaccinated will also become infected.

In the U.S., measles cases can originate from international travel as the disease remains common in many parts of the world. Typically, 2 out of 3 of travelers with measles are unvaccinated Americans re-entering the country.

As seen by the recent outbreaks across the country, measles can spread rapidly, and infected individuals can spread measles to other people who are not immune.

AI optimizes the quest for small molecules

Our scientists harness rapidly evolving tech in small molecule lead optimization, which aims to improve biological activity, target selectivity and potential for toxicity

February 26, 2025

Share this article

.st0{fill:#00857C;}

article hero thumbnail
Assets / Buttons / UI / Play Button / Large clear hover

  

The aim in lead optimization is to improve biological activity, target selectivity and potential for toxicity. During this phase of drug discovery, we use artificial intelligence and machine learning (AI/ML) to enhance the properties of lead compounds and evaluate their effects on various biological properties. 

The landscape for AI/ML is evolving and maturing at an incredible rate. The convergence of increasing access to relevant data, exponentially available computing power, and advancements in deep-learning algorithms has led to unprecedented opportunities to dramatically accelerate and improve the discovery of new drugs.

scientist

Explore R&D careers

We’re looking for next-gen scientists and technologists who are passionate about making a difference for patients. 

Health awareness

Sarampión: signos y síntomas

Obtenga más información sobre qué es el virus del sarampión y cómo se propaga

February 19, 2025

Share this article

.st0{fill:#00857C;}

Little girl with measles
mom holding child with measles

¿Qué es el sarampión?

El sarampión es una enfermedad viral altamente contagiosa que puede afectar a personas de todas las edades, pero es más común en los niños. El virus vive en la mucosidad de la nariz y en la garganta de una persona infectada.

El sarampión se propaga por el aire cuando una persona infectada tose o estornuda. Los síntomas aparecen entre 7 y 14 días después del contacto con el virus.

Los síntomas comunes del sarampión incluyen los siguientes:

Fiebre alta

(puede subir repentinamente a más de 104 °F)

Tos

Moqueo

Ojos rojos y llorosos

(conjuntivitis)

Manchas en la boca

(2-3 días después de que comiencen los síntomas)

Erupción

(3-5 días después de que comiencen los síntomas)

Cómo se propaga el sarampión

icon
¿El sarampión se transmite por el aire?

El virus del sarampión puede permanecer hasta dos horas en el ambiente después de que una persona infectada abandona un sitio.

icon
¿Qué tan contagioso es el sarampión?

Si una persona tiene sarampión, hasta el 90% de las personas no vacunadas que se encuentren cerca de ella también se infectarán.

icon
¿Por cuánto tiempo es contagioso el sarampión?

Las personas infectadas pueden transmitir el sarampión a otras entre cuatro días antes y cuatro días después de que aparezca la erupción

icon
¿Cuánto dura el período de incubación del sarampión?

Después de estar expuesto al virus del sarampión, este puede incubarse por hasta 21 días.

icon
¿El sarampión causa complicaciones?

El sarampión puede causar complicaciones de salud. Las más comunes son las infecciones de oído y la diarrea. Las complicaciones graves incluyen neumonía y encefalitis (inflamación del cerebro). El sarampión puede afectar la vida diaria de los pacientes y de sus cuidadores (por ejemplo, puede dar lugar a una pérdida de horas de trabajo o días de escuela).

El sarampión puede ser grave y causar complicaciones 

  • Aproximadamente 1 de cada 5 personas no vacunadas en los EE. UU. que contraen sarampión se hospitalizan.
  • Hasta 1 de cada 20 niños con sarampión contrae neumonía, que es la causa más común de muerte por sarampión en niños pequeños.
  • Aproximadamente entre 1 y 3 de cada 1,000 niños que se infectan de sarampión morirán por complicaciones respiratorias y neurológicas.

Brotes de sarampión

Antes de la disponibilidad de la vacuna en 1963, se estima que entre 3 y 4 millones de estadounidenses contraían sarampión cada año, y se calcula que 48,000 personas en Estados Unidos se hospitalizaban y se producían aproximadamente entre 400 y 500 muertes al año.

icon

El sarampión endémico (que ocurre regularmente dentro de un área o una comunidad) se declaró erradicado en los EE. UU. en el año 2000.

icon

En 2019, se registró el mayor número de casos de sarampión notificados en Estados Unidos desde 1992.

icon

En 2024, se han producido brotes continuos de sarampión. Hasta julio, se han notificado 13 brotes de sarampión en los Estados Unidos.

Los casos de sarampión han aumentado en los Estados Unidos

Hasta julio de 2024, se confirmaron 167 casos de sarampión en los EE. UU.

Cuando usted se contagia de sarampión, hasta el 90% de las personas a su alrededor que no estén vacunadas también se infectarán.

En los Estados Unidos, los casos de sarampión pueden originarse en viajes internacionales, ya que la enfermedad sigue siendo común en muchas partes del mundo. Por lo general, 2 de cada 3 viajeros con sarampión son estadounidenses no vacunados que reingresan al país.

Como lo demuestran los brotes recientes en todo el país, el sarampión se puede propagar rápidamente y las personas infectadas pueden contagiar a personas que no son inmunes.

Innovation

Our Q4 and full-year 2024 financial results

February 4, 2025

Share this article

.st0{fill:#00857C;}

illustration

Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. ​

​“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, the successful launch of WINREVAIR and strong performance of our Animal Health business,” said Rob Davis, chairman and chief executive officer. “We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development. Our business remains well positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential.”​

​Merck anticipates full-year 2025 worldwide sales to be between $64.1 billion and $65.6 billion.​

Find more details on Q4 and full-year 2024 results below.​

Download infographic

Innovation

Our researchers incorporate LLMs to accelerate drug discovery and development

What are artificial intelligence (AI) agents? They're intelligent systems combining large language models (LLM), AI models and tools to iteratively plan, execute and optimize tasks

February 3, 2025

Share this article

.st0{fill:#00857C;}

illustration of octopus multitasking

Did you know that LLMs can be leveraged as master multitaskers? These LLM-based multitaskers, often called AI agents, can execute different tasks simultaneously. Having a team of high-performing AI assistants that can each play different roles ultimately helps researchers at Merck Research Labs (MRL) focus on critical drug discovery and development.

In today’s data-driven world, AI agents are emerging as a powerful tool for researchers and scientists to aid them in navigating the complexities of large data sets, refining hypotheses and executing both repetitive and differentiated tasks efficiently. Done manually, that kind of data gathering and analysis costs time and money.

Merck researchers use AI to augment human ability

A long-standing ambition for AI is to help find major scientific discoveries, learn on its own and acquire knowledge autonomously. This is what some call an “AI scientist.” While this concept is aspirational, advances in agent-based AI can help pave the way for the development of AI agents as conversable systems capable of reflective learning and reasoning that coordinate LLMs, machine learning (ML) tools, or even combinations of them.

Rather than taking humans out of the discovery process, AI can augment human ability to break down a problem into manageable subtasks, which can then be addressed by AI agents with specialized functions for targeted problem solving and integration of scientific knowledge. One significant advantage of these collaborative systems is their capacity for automation. Repetitive tasks, such as data cleaning or preliminary analysis, can be handled by AI agents, freeing our scientists to focus on higher level work and strategic decision making.

“We’ve already deployed AI agents, including in development workflows like medical writing, where agents query and assemble knowledge, and evaluate both human and AI writing.”

  • Matt Studney
    Vice president, information technology, MRL

“We see broad applicability of AI agents, for example in orchestrating discovery workflows, where agents can help researchers in generating molecular design ideas and insights, optimize assay workflows and generate biology insights integrated across cells, organisms and human genomics,” he said. “We see agents making the R&D process faster and crucially driving higher quality results. Agents help capitalize on Merck’s long-standing investments in AI/ML by rapidly accelerating the speed of our human researchers at scale.”

Advance your data science career with us

We’re looking for scientists and technologists who are passionate about making a difference for patients.

Health awareness

Make time to get screened for cancer

Find out why it's important to follow cancer screening recommendations

January 15, 2025

Share this article

.st0{fill:#00857C;}

woman talking with her doctor
Assets / Buttons / UI / Play Button / Large clear hover

We’ve all had the feeling that there aren’t enough hours in the day. In between everything else on the to-do list, it can feel hard to make your health and annual appointments a priority. However, it’s important to take control of your health and talk to your doctor about what cancer screenings might be recommended for you.

Why timing matters in cancer screening

Time is important with a cancer diagnosis so that treatment can be started early, before cancer has spread to other parts of the body. Cancer screenings can increase the chance of finding disease before a person has symptoms or when cancer is still in earlier stages.

There are screening guidelines for many types of cancer, such as breast, colorectal and lung cancer, as well as melanoma. Screening recommendations often take into consideration a few factors, such as age, family history and lifestyle. Your doctor can help you identify which screenings might be right for you.

As a leader in oncology, we’re committed to addressing the global impact of cancer.

“Through our work to increase access to screening and our other initiatives and programs, we appreciate the importance of finding disease early, before it has spread to help enable early treatment, because we believe people with cancer deserve more,” said Linda Kollmar, associate vice president, medical affairs, value and implementation.

So, make time now to talk to your doctor and to find out if you’re eligible for cancer screening.

We’re working to help address other barriers to cancer screening

Raising awareness about cancer screening is just one way our company works to help improve lives. We also strive to help address barriers to screening and treatment, which is why we work with partners around the globe to support public health initiatives that support recommended screening and create access to high quality cancer care for all patients.

Our support of the American Cancer Society’s Get Screened initiative makes it possible for community members to be screened for breast, cervical, colorectal and lung cancer who might not have access otherwise. And working with City Cancer Challenge, we support the Patient Navigation Program in Kigali, Rwanda to train nurses as patient navigators who can help people understand health information more easily and gain access to health care options more quickly.

Find out more about how we collaborate with partners around the world to help make cancer care more accessible.

Sustainability

In memory of President Jimmy Carter, 1924–2024

Honoring a life and legacy of profound impact for global health

December 29, 2024

Share this article

.st0{fill:#00857C;}

Former President Jimmy Carter and retired Merck CEO Roy Vagelos meet with people affected by river blindness

Former President Jimmy Carter exemplified a life of service, first through his governorship and presidency, and later through the Carter Center and its commitment to improving the health and well-being of those most in need. We are privileged to have worked side-by-side with President Carter and the Carter Center on its ongoing work to eliminate river blindness in countries throughout Africa and Latin America.  

Over decades of our partnership through the Mectizan® Donation Program, the Carter Center has distributed more than 500 million treatments in our shared efforts to donate Mectizan — as much as needed, for as long as needed. 

While President Carter did not want to take credit for the program, all of us at Merck know it was his leadership and commitment to global health that made this a reality.

We share in the grief of all those whose lives have been touched by President Carter. They are a living testament to his compassion, selflessness and generosity.

President Carter’s memory will guide and inspire us as we continue our work for patients and communities. 

May he rest in the peace he wished for the world.

Pictured above: Jimmy Carter and retired Merck CEO Dr. Roy Vagelos meet with people affected by river blindness, 1994.

Innovation

Podcast: How AI can improve insight into disease biology

A scientist explains how we’re using AI capabilities to help identify patterns in tissue and tumor samples indiscernible to the human eye

December 18, 2024

Share this article

.st0{fill:#00857C;}

Microphone with blue soundwaves

We see the potential of data science, artificial intelligence (AI) and machine learning (ML) to help investigate new areas, pathways and mechanisms that may forge new opportunities to strengthen our pipeline through enhanced insights.

In a recent episode of the Health Pulse podcast by SAS, Dr. Greg Goldmacher, associate vice president, clinical research, and head of clinical imaging and pathology at Merck, discussed how we’re using these AI capabilities, like computer vision, to improve disease biology insights and help with objective imaging analysis to identify patterns indiscernible to the human eye.

“If you have AI tools that are trained to pick up subtle early signs of disease on scans that are being done for other reasons, there’s a real opportunity there for earlier diagnosis,” said Goldmacher in the podcast episode. “If you’re going to do opportunistic screening, for example, and want to train AI for that, what you need is longitudinal data sets where you can find patients who had the disease, and then go and look for scans that they might have had in the past to use to train the disease-recognizing models.”

photo of Greg Goldmacher

Listen to the podcast

Read the transcript

Advance your data science career with us

We’re looking for scientists and technologists who are passionate about making a difference for patients.

Innovation

Building on our understanding of gynecologic cancers

How we’re driving research forward for women with common types of gynecologic cancer

December 16, 2024

Share this article

.st0{fill:#00857C;}

patient and doctor

By the numbers, the impact of gynecologic cancers feels overwhelming. The term “gynecologic cancers” primarily refers to cancers of three organs: the uterus, ovaries and cervix. As of 2022, these gynecologic cancers are some of the most commonly occurring cancer types for women worldwide. Even with advances in prevention and treatment, nearly 700,000 are projected to die from these diseases every year.

“To truly understand where we can begin to make progress, we need to look beyond the numbers,” said Dr. Gursel Aktan, vice president, global clinical development.

Understanding the trend

While “gynecologic cancers” primarily refers to the three cancer types mentioned above, it may also include cancers of the fallopian tube, vagina, and vulva.

Dr. Gursel Aktan

“While the gynecologic cancer rates vary from country to country, the overall incidence rates of endometrial and cervical cancers have increased over time.”

  • Dr. Gursel Aktan

Endometrial cancer, which affects the lining of the uterus, is the most common gynecologic cancer in developed countries. Incidence rates for cervical and endometrial cancers, which mainly affect post-menopausal women, have been rising globally over the last two decades. The highest rates of diagnosis and death from gynecologic cancers were found in Eastern and Southern Africa and Melanesia.

“Unfortunately, many women may not recognize their symptoms as abnormal until their tumors are larger or may have spread,” said Dr. Aktan.

Building on what we have learned

“As our understanding of cancer continues to improve, there have been meaningful advances in cancer therapy, but we still have work to do to achieve our goal of helping more patients,” said Dr. Aktan.

To build on that momentum, we’re driving forward research focused on novel approaches for patients with certain gynecologic cancers with ~12 clinical trials for ~8,000 patients around the world. This work is grounded in our company’s three key focus areas in oncology research:

  • Evaluating combinations that play different roles in adjusting the immune response.
  • Precision molecular targeting to impact pathways that drive cancer growth.
  • Investigating ways to increase cancer cell sensitivity to immune responses.

“We’re also still learning about the right sequence in which to use treatments, and the truth is, the answers may be different tumor by tumor, patient by patient,” said Dr. Aktan.

“The better we understand how we can use these approaches to further cancer care, the closer we move toward our ultimate goal of supporting patients touched by cancer.”

  • Dr. Gursel Aktan

Learn more about our work in oncology.

Sustainability

How we’re addressing health literacy

Many people struggle to understand health information, which can impact health outcomes. What we're doing to support health literacy.

December 6, 2024

Share this article

.st0{fill:#00857C;}

two senior adults reviewing health care information with a provider

What is health literacy?

At points in our lives, we need to make health or medical decisions for ourselves, members of our family or those in our care.  And sometimes it can be challenging. Whether it’s deciding to receive a vaccine, start a new medication, undergo a procedure or join a clinical trial, our level of health literacy — the ability to find, understand and use information and services — can play an important role in health outcomes. Unfortunately, when people struggle, there may be negative health consequences, like decreased adherence to treatment plans, increased emergency room visits and hospital stays, and higher mortality rates.

Low health literacy is more common in vulnerable populations

While limited health literacy can affect anyone, there are certain populations at greater risk: older adults, racial and ethnic minorities, those with low income or less education, and people with compromised health status.

“As a company committed to helping save and improve lives, it’s our responsibility to communicate in a way that people can understand so that they can make informed health decisions,” said Shehla Hussain, director, medical writing safety services.

Health literacy is important for health equity

People with better health literacy are more likely to proactively engage in disease preventive behaviors and make informed decisions about their well-being. On the other hand, people with lower or limited health literacy may struggle to understand relevant information, leading to an increased risk of poor health outcomes.

How we’re making medical information easier to understand

We’re committed to making sure the information we share with the world is very clear. It’s something we’ve focused on since 2011, long before the U.S. Department of Health and Human Services updated the definition of health literacy in 2020 to acknowledge that organizations have a responsibility to equitably enable individuals to find, understand, and use information and services to inform health-related decisions and actions for themselves and others.

As part of our efforts, we created a plain language glossary and established company-wide standards focused on improving the health literacy of the information in our resources and materials. It starts in product development and continues through the life cycle of the product, including clinical trials, labeling, post-approval, marketing and promotional materials. For example, we’re:

  • Creating easy-to-read patient labels
  • Improving packaging and instructions for use
  • Developing easy-to-understand disease educational materials
  • Improving health literacy within clinical trials
  • Expanding our plain language glossary of medical/scientific terms
  • Supporting research on health literacy
  • Utilizing plain language and graphics in digital and online resources
  • Sharing best practices externally

We also listen to the people who use or may use our products to help guide our efforts.

article quote image

“We work to build trust by listening to the communities we serve, understanding their needs and making our information clear, concise and understandable.”

– English D. Willis

Executive director, clinical safety and risk management, and executive sponsor, Health Literacy Community of Practice

Reducing health disparities around clinical trials

Within our clinical trials, we strive to reduce health care disparities by increasing diverse representation in our clinical trials.

“Health literacy is critically important for achieving clinical trial diversity as it ensures that individuals from diverse backgrounds can understand trial information, make informed decisions and effectively participate. Improving health literacy is essential for equitable access and participation, fostering greater inclusivity in research, leading to more representative and impactful outcomes” said Luther Clark, executive director, medical affairs, patient innovation and engagement.

Euvon Jones, a clinical trial participant, said: “Knowledge is power, and during my journey with prostate cancer, I realized the importance of fully understanding my diagnosis and the options available to me. Through conversations with my doctor and loved ones, and seeking information from reliable sources, I felt empowered to make informed decisions. When we fully understand the importance of the health information we receive, we’re better equipped to navigate the health care system, communicate with providers and advocate for the best possible care.”

Look at some examples of our work

Defining complex medical terms in plain language

By defining common terms used by health care providers, patients feel more prepared and confident to engage in discussions with their care teams.

Easy to navigate website

Understanding the patient's perspective allowed us to create a website that anticipates their needs for easy navigation. Plainer language, effective visuals and simple layouts make the website a useful tool.

health literacy retinopathy

Seeing from the patient perspective

In a diabetes awareness brochure, we presented the view from the patient's perspective so they can see the potential effects of eye damage from diabetes.

“And our work isn’t done. While we continue to learn and engage with communities, we’re also learning better ways to communicate with our consumers, patients and the general public.”

– English D. Willis